These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15237653)

  • 21. Antineoplastic vesicant extravasation.
    Beason R
    J Intraven Nurs; 1990; 13(2):111-4. PubMed ID: 2313459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation.
    Lawrence HJ; Walsh D; Zapotowski KA; Denham A; Goodnight SH; Gandara DR
    Cancer Chemother Pharmacol; 1989; 23(5):316-8. PubMed ID: 2706738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Subcutaneous "wash-out" in extravasations].
    Giunta R; Akpaloo J; Kovacs L; Biemer E
    Handchir Mikrochir Plast Chir; 2002 Nov; 34(6):399-402. PubMed ID: 12601608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extravasation of chemotherapeutic agents: prevention and treatment.
    Goolsby TV; Lombardo FA
    Semin Oncol; 2006 Feb; 33(1):139-43. PubMed ID: 16473651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines.
    Pérez Fidalgo JA; García Fabregat L; Cervantes A; Margulies A; Vidall C; Roila F;
    Ann Oncol; 2012 Oct; 23 Suppl 7():vii167-73. PubMed ID: 22997449
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of extravasation of both doxorubicin and vincristine administration in a Y-site infusion.
    Comas D; Mateu J
    Ann Pharmacother; 1996 Mar; 30(3):244-6. PubMed ID: 8833558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic therapy emergencies.
    Albanell J; Baselga J
    Semin Oncol; 2000 Jun; 27(3):347-61. PubMed ID: 10864222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of antidotes for extravasation injury produced by 6-hydroxymethylacylfulvene (MGI 114), a novel cytotoxic antitumor agent, in an intradermal toxicity model in rats.
    Marshall RF; Arthaud LE; MacDonald JR
    Cancer Chemother Pharmacol; 2000; 45(5):397-401. PubMed ID: 10803923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extravasation management.
    Schulmeister L
    Semin Oncol Nurs; 2007 Aug; 23(3):184-90. PubMed ID: 17693345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of hyaluronidase for the treatment of extravasation of chemotherapeutic agents in six dogs.
    Spugnini EP
    J Am Vet Med Assoc; 2002 Nov; 221(10):1437-40, 1419-20. PubMed ID: 12458613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Introduction of a clinical protocol for extravasation at the National Institute of Oncology, Budapest, Hungary].
    Bartal A; Mátrai Z; Rosta A; Szûcs A
    Magy Onkol; 2011 Mar; 55(1):14-20. PubMed ID: 21617787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity to topical dimethyl sulfoxide (DMSO) when used as an extravasation antidote.
    Creus N; Mateu J; Massó J; Codina C; Ribas J
    Pharm World Sci; 2002 Oct; 24(5):175-6. PubMed ID: 12426960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dimethyl sulfoxide therapy in the treatment of vesicant extravasation: two case presentations.
    St Germain B; Houlihan N; D'Amato S
    J Intraven Nurs; 1994; 17(5):261-6. PubMed ID: 7965372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cytostatic drug extravasation--are there new recommendations for therapeutic management?].
    Fenchel K; Karthaus M
    Wien Med Wochenschr; 2001; 151(3-4):44-6. PubMed ID: 11789418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Topical dimethyl sulfoxide and intralesional hyaluronidase administration for vinorelbine extravasation-induced rat skin injury].
    Zhu QC; Luo RC; Miao JX; Li AM; Liang WJ; Luo YL; Dai M
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Sep; 27(9):1444-6. PubMed ID: 17884798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of adriamycin-induced full-thickness skin loss using hyaluronidase infiltration.
    Disa JJ; Chang RR; Mucci SJ; Goldberg NH
    Plast Reconstr Surg; 1998 Feb; 101(2):370-4. PubMed ID: 9462769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extravasation of systemic hemato-oncological therapies.
    Ener RA; Meglathery SB; Styler M
    Ann Oncol; 2004 Jun; 15(6):858-62. PubMed ID: 15151940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vesicant extravasation part I: Mechanisms, pathogenesis, and nursing care to reduce risk.
    Sauerland C; Engelking C; Wickham R; Corbi D
    Oncol Nurs Forum; 2006 Nov; 33(6):1134-41. PubMed ID: 17149396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of mitoxantrone extravasation.
    Chang A
    J Oncol Pharm Pract; 2020 Jul; 26(5):1270-1273. PubMed ID: 31902285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of extravasation injuries: a focused evaluation of noncytotoxic medications.
    Reynolds PM; MacLaren R; Mueller SW; Fish DN; Kiser TH
    Pharmacotherapy; 2014 Jun; 34(6):617-32. PubMed ID: 24420913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.